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Depression and anxiety are common in Parkinson’s disease (PD) and have important consequences on quality of life. These have
long been recognized as frequent accompanying syndromes of PD, and several reports suggest that these are the causative process
orrisk factors that are present manyyears before the appearance of motorsymptoms. The neurochemical changes in PD involving
dopamine, norepinephrine, and serotonin might be related to the pathophysiology of depression and anxiety, but this is still not
clear. Several studies showed that anxiety in PD patients occurs earlier than depression, during premotor phase, suggesting that
there may be a link between the mechanisms that cause anxiety and PD. Whereas a recent study reported that PD patients with
depression and anxiety were associated with diﬀerent demographic and clinical features.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
that results in progressive extrapyramidal motor dysfunc-
tion primarily related to loss of dopaminergic nigrostri-
atal function. The loss of dopamine leads to diﬃculty
with movement, including slowness or lack of movement,
rigidity, and resting tremor. Though less acknowledged,
non-motor symptoms (NMSs) in PD are common and
were recognized by Parkinson himself [1]. He referred
to urinary incontinence, constipation, sleep disturbance
and delirium. PD patients also suﬀer from a variety of
NMSs, including signiﬁcant changes in emotional well-
being that deleteriously impact their quality of life [2].
O’Sullivan S. S. et al. attempted to correlate NMSs in PD
by reviewing medical histories of pathologically identiﬁed
patients. Twenty-one percent of patients presented with
NMSs including pain, urinary dysfunction, depression,
and anxiety [3]. In addition, premorbid personality traits
consisted of cautiousness, inﬂexibility, introversion, and
lack of novelty seeking, which also persist after the onset
of motor illness. It has been suggested in the general
population study that these traits, as well as the low
premorbid rates of coﬀee drinking and alcohol consump-
tion, may reﬂect an underlying damage to the mesolimbic
dopaminergic pathways among individuals predisposed to
PD [4].
However, the NMSs of PD are not well recognized in
clinical practice and one US study reported that existing
depression, anxiety, and fatigue are not identiﬁed by neu-
rologists in 50% of consultations, and sleep disturbances are
not identiﬁed in over 40% of consultations [5]. Psychiatric
symptoms may be missed if a clinician’s interest is mainly
focused on motor impairment. Patients’ reluctance to report
psychological symptoms may also contribute to the limited
detection of these disorders.
This paper is a review of current data on psychiatric
features in PD, speciﬁcally depression and anxiety, which
are important determinants of quality of life, and, therefore,
requires early detection and intervention.2 Parkinson’s Disease
2.When Do Depression and
Anxiety Occurin PD?
PD cannot be clinically diagnosed until motor symptoms
appear, and it is commonly thought that NMSs occur only
in late or advanced PD. However, NMSs can indeed present
at any stage of the disease, including the early and pre-motor
phase [6–9]. Several case-control or cohort studies suggest
that anxiety may be one of the earliest manifestations in
PD. In a population-based, case-control study, PD patients
historical medical records were examined for depression and
anxietyinpre-motorphaseofPD(Table 1).Thisﬁndingheld
trueevenwhentheanalysiswentasfarbackas20yearsbefore
the onset of motor symptoms [10]. In addition, the Health
Professionals Follow-up study showed that “phobic anxiety”
was a signiﬁcant risk factor for the development of PD
[11], and the composite Minnesota Multiphasic Personality
Inventoryofneuroticism also showed that patientswith high
anxiety were at an increased risk for PD [12].
While the previously mentioned articles do not look at
or show a link between depression and PD, there are several
supporting articles. One study found that the initiation of
any antidepressant therapy was associated with a higher risk
of PD within 2 years after the start of treatment, suggesting
that depressive symptoms could be an early manifestation of
PD [14]. The second study used a self-report of depression
anduseofpsychotropicmedicationtoidentifyalinkbetween
depression and PD [15].The third study lookedat a database
of medical histories in the Netherlands and found a positive
association between depression and subsequent incidence of
PD[13].W hilether ear esomedisparitiesbetweendepr ession
and PD during the pre-motor phase, all the articles that have
looked at anxiety and PD have shown a link, suggesting that
there may be an association between the mechanism that
causes anxiety and PD. In summary, these reports show that
anxiety and depression are associated with PD and suggest
that the causative process or risk factors underlying PD
may be present many years before the appearance of motor
symptoms.
3.Depression
Accoriding to DSM-IV criteria, a major depressive disorder
is deﬁnited as a person who must either have a depressed
mood or a loss of interest or pleasure in daily activities
consistently for at least a two-week period in addition to
fatigue, insomnia, weight loss, and so on. It is estimated that
between30–45%ofPDpatientsaredepressed,whichreduces
both subjective and objective quality of life independent of
motor deﬁcits [16–19]. By contrast, the average prevalence
of clinically relevant depression in an age-matched group of
the general population is roughly 13.5% [20].
One potential explanation for this increased prevalence
of depression is the damage that PD has on the dopamin-
ergic, serotonergic, and noradrenergic systems [21]. Remy
et al. [22]u s e d[ 11C]RTI-32 PET, an in vivo marker of
both dopamine and noradrenaline transporter binding, to
localize diﬀerences between depressed and nondepressed
PD patients. Depressed PD patients had lower [11C]RTI-32
binding than nondepressed PD patients in the limbic system,
but also in locus coeruleus, which is the noradrenergic
nucleus. They suggested that depression in PD might be
associated with a loss of dopamine and noradrenaline
innervations in the limbic system. A randomized, controlled
trial of paroxetine CR (selective serotonin reuptake inhibitor
(SSRI)), nortriptyline (Tricyclic antidepressant (TCA)), and
placebo in patients with PD and depression showed that
Nortriptyline was eﬃcacious in the treatment of depression
and paroxetine CR was not [23]. However, Atomoxetin
(selective norepinephrine reuptake inhibitor (SNRI)) was
not eﬃcacious for the treatment of depression in PD [24].
TCA is a dual (serotonin and noradrenaline) reuptake
inhibitor, SSRI inhibits only serotonin, and SNRI inhibits
only noradrenaline; therefore, it is possible that the mech-
anism of the apparent superiority of nortriptyline is its eﬀect
on norepinephrine besides serotonin.
The ﬁrst randomized study done by Rektorova et al.
showed possible antidepressive eﬀects, not dependent on
motor improvement of pramipexole (PPX) as compared to
pergolide [25]. PPX, a D2/D3 receptor agonist, preferentially
acts on D3 receptors in the brain, while pergolide preferen-
tially acts on D2 receptors. We found that PPX has beneﬁts
for depressive symptoms in PD patients, and antidepressant
eﬀects did not depend on motor functional improvement
[26]. These results suggest that the original serotonergic
and noradrenergic hypotheses of depression do not fully
account for the neurobiology of depression or mechanism
of action of eﬀective antidepressants. In addition, there is
ae ﬃcacious diﬀerence among dopamine receptor agonist.
Roy et al. [27] found lower cerebrospinal ﬂuid levels of
homovanillic acid (HVA), which is a dopamine metabolite
found at lower levels in depressed subjects. In addition,
direct measurement of brain monoamine metabolites from
the internal jugular vein of patients resistant to depres-
sion treatments revealed low HVA levels that were highly
correlated with illness severity [28]. These results support
the monoaminergic theories of depression, which hold that
dysregulation of PD system, involving dopamine in addition
to serotonin and norepinephrine, may also be involved in
depression.
Ropinirole, another D2/D3 agonist, acts on D3 prefer-
entially and showed eﬀects on NMSs in PD patients with
motor ﬂuctuations and/or dyskinesias [29]. In addition,
Pahwa et al. reported in a double-blind placebo-controlled
study, that Ropinirole improved NMSs in PD patients [30].
When comparing other dopamine agonists which act on D2
preferentially, bromocriptine worsened psychotic symptoms
in patients suﬀering from schizophrenia, other psychotic
disorders, or psychotic depression [31]. Pergolide works well
to treat PD, but this dopamine agonist has no eﬃcacy on
depression in PD [25]. In contrast, PPX, which is a nonergot
dopamine agonist showed an antidepressant eﬀect in the
double-blind study with Placebo [32]. These eﬀects may
relate to PPX’s preference for D3 versus D2 receptors and
neurotrophic properties. In addition, D3 receptors are more
abundant in limbic system than D2 receptors and play an
important role in neuronal circuits implicated in depressive
states.Parkinson’s Disease 3
Table 1: Depression and anxiety in pre-motor phase of PD.
Syndrome Reference Prevalence Notes
Depression Schuurman et al. (2002) [13] Hazard ratio 3.13 The relative risk of depressed individuals developing PD
Alonso et al. (2009) [14] Rate ratio 1.85 The ratio of PD who initiates antidepressant therapy compared
with noninitiators
Anxiety
Shiba et al. (2000) [10] Odds ratio 2.2 The frequency of preceding anxiety in PD compared with control
subjects
Weisskopfet al. (2003) [11] Relative risk 1.6 Risk of PD relative to use of anxiolytic medication
Bower et al. (2010) [12] Hazard ratio 1.63 The relative risk of anxious personality developing PD
Depression and
anxiety Jacob et al. (2010) [15] Odds ratio 1.42 The frequency of receiving a diagnosis of depression or anxiety
prior to PD
SSRI and TCA are two major categories of antidepres-
sants commonly used to treat depression. SSRIs appear to
be tolerated; however, an Italian multicenter study reported
that the proportion of patients who recovered, as deﬁned
by a ﬁnal Hamilton Depression Rating Scale score ≤8,
was signiﬁcantly higher in the PPX group as compared to
sertraline (an SSRI) group [33]. TCAs have been shown
to be eﬀective in treating depression in PD patients, while
SSRIs have no eﬀect compared to placebo. However, some
problems may arise with TCA due to side eﬀects such as
sedation and orthostatic hypotension [23, 34].
4.Anxiety
Anxiety is a common NMSs among patients with PD and
has a reported prevalence of 25–49% [16, 35], which is
much higher than what is seen in non-PD subjects. Panic
disorder, generalized anxiety disorder, and social phobia
are the most common anxiety disorders reported. Anxiety
and depression may be diﬃcult to distinguish; however,
unlike depression, a core feature of anxiety is the presence
of apprehension, fear, or worry. The severity, but not the
duration of PD, was positively related to anxiety. In addition,
PD patients with postural instability and gait dysfunction
symptom clustering were more likely to experience anxiety
than tremor-dominant patients. Levodopa dosage had no
relationship to anxiety; however, experience of dyskinesias
oron/oﬀﬂuctuationsincreasedtheriskofanxiety.Anxietyin
PDcontributedtoapoorqualityoflife,andyoungerpatients
(<62 years) were more likely to experience anxiety disorder.
Nortriptyline was signiﬁcantly better than Paroxetine CR,
and placebo in alleviating anxiety [23]. In addition, Atom-
oxetine,treatedpatientsshowed decreasedseverityofanxiety
comparedwith Placebogroup[24].There was noassociation
between patients who had functional neurosurgery for
PD and anxiety; however, history of psychiatric disorders
increased the risk for a diagnosis of current anxiety [35].
Anxiety and PD could share some underlying bio-
logical mechanisms that lead to them occurring at any
stage of disease including pre-motor phase. Abnormalities
in dopaminergic transmission are associated with anxi-
ety. Striatal dopamine receptor binding was found to be
reduced in both nonhuman primate models of anxiety
and humans with anxiety disorders. Humans with anxiety
disorders also appear to have reduced levels of dopamine
uptake in the striatum and reduced level of homovanillic
acid in cerebrospinal ﬂuid. Other neurotransmitter systems,
including those of nonepinephrine, serotonin, acetylcholine,
and γ-aminobutyric acid, may also play a role in anxiety as
suggested by the results of animal experiments and pharma-
cologicalstudiesin humans [36, 37].These neurotransmitter
systems interact with dopaminergic system and might be
aﬀected in PD patients.
5.CoexistenceofDepression and AnxietyinPD
Depression and anxiety are frequently associated in the
same patients, and this can be seen as an argument to
support the hypothesis that these two symptoms may share
common pathophysiological mechanisms. Dissanayaka et
al. reported that comorbid depression with anxiety was
observed in 14% of PD patients [35]. While Negre-Pages
et al. found that anxiety and depression in patients with
PD were associated with diﬀerent demographic and clinical
factors [38]. They also found that PD patients with anxious
symptoms were more frequently female and younger than
those without suchsymptoms, whereas thosewith depressive
symptoms had more severe indices of parkinsonism, more
comorbidities, and lower cognitive function. These studies
support the hypothesis that anxiety and depression may
refer to diﬀerent mechanisms since they are not correlated
to the same features in PD. Anxiety may be more related
to nonspeciﬁc factors, comparable to those observed in
the general population, while depression may be more
linked to the dopaminergic denervation that characterizes
PD.
6.Conclusions
Depression and anxiety in PD can occur at any stage of
disease including pre-motor phase and are more frequent
in PD patients than in controls. While the link between
depression and PD during the pre-motor phase is not
clear, all the articles reviewed in this paper support a link
betweenanxietyandpre-motorphasePD.Thissuggeststhere
may be an association between the mechanism that causes
anxiety and PD. However, a recent study reports that PD
patients with depression and anxiety were associated with
diﬀerent demographic and clinical features. Further studies
are needed to elucidate these diﬀerences.4 Parkinson’s Disease
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